Safety of Intravenous Thrombolysis in Ischemic Stroke Caused by Left Atrial Myxoma

Author(s): Maurizio Acampa, Rossana Tassi, Francesca Guideri, Giovanna Marotta, Lucia Monti, Gianni Capannini, Alfonso Cerase, Giuseppe Martini

Journal Name: Current Drug Safety

Volume 6 , Issue 5 , 2011

Become EABM
Become Reviewer


Intravenous thrombolytic treatment represents the gold standard for acute ischemic stroke treatment. However there is some concern to perform this treatment in patients with known cardiac myxomas for the risk of haemorragic complications. Here we described a 63-year-old patient with ischemic stroke due to embolization of atrial myxoma and treated with intravenous recombinant tissue plasminogen activator alteplase. The patient did not show improvement after treatment; 25 days later a brain CT showed an asymptomatic small hemorrhagic infarction, probably due to the large size of ischemic lesion. The lack of response might be explained by the embolization of a large tumor fragment. One-year after cardiac surgery clinical follow-up did not reveal new neurological signs nor symptoms. This case report suggests that systemic thrombolysis is a safe procedure also in patient with atrial myxoma. The efficacy of therapy seems to be related to embolus composition.

Keywords: Stroke, atrial myxoma, thrombolysis, Intravenous thrombolytic treatment, cardiac myxomas, haemorragic complications, intravenous recombinant tissue plasminogen activator alteplase, ischemic lesion

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [343 - 345]
Pages: 3
DOI: 10.2174/157488611798918665
Price: $65

Article Metrics

PDF: 11